NURS FPX 4055 Assessment 4 Health Promotion Plan Presentation
NURS FPX 4055 Assessment 4 Health Promotion Plan Presentation
Name
Capella university
NURS-FPX4055 Optimizing Population Health through Community Practice
Prof. Name
Date
Health Promotion Plan Presentation
Introduction and Presentation Roadmap
Good morning, and thank you for joining today’s health session. We are pleased to welcome our partners and participants to this important discussion. Today’s presentation focuses on preventing Human Papillomavirus (HPV) infections in adolescents and young adults between the ages of 11 and 26, specifically targeting the community of Schwenksville, Pennsylvania. This session aims to raise awareness about the health risks associated with HPV, including its links to various cancers, while promoting timely immunization and strategies for discussing the HPV vaccine with others. The presentation is framed around previously established SMART goals and aligns with national objectives outlined in Healthy People 2030.
The roadmap for this session includes six primary components. First, we will present key facts about HPV, including how it spreads and its connections to cancer. Next, we will discuss the safety, efficacy, and importance of the HPV vaccine. We will then encourage participants to commit to scheduling their vaccination within 30 days. The session also aims to boost participants’ confidence in talking about the vaccine with family members and healthcare providers. Interactive elements, including discussions and activities, will keep the session engaging. Finally, we will assess participants’ understanding through a post-session quiz and confidence survey.
HPV Facts, Vaccination Benefits, and Communication Strategies
HPV is a highly common virus, primarily transmitted through sexual activity and skin-to-skin contact. Despite its prevalence, HPV remains largely preventable through vaccination. In Pennsylvania, vaccination coverage remains insufficient—only 68.7% of adolescents are fully vaccinated, and rural areas like Schwenksville report even lower rates at 48.7% (PA.gov, 2025). These low rates contribute to elevated cancer incidence and mortality. HPV is responsible for several cancers, including cervical, anal, genital, and throat cancers. High-risk strains such as HPV 16 and 18 can persist undetected and cause long-term cellular damage leading to cancer (Huber et al., 2021).
The benefits of timely HPV vaccination are numerous. The vaccine is most effective when administered at ages 11 or 12, before exposure to HPV. Early immunization elicits a stronger immune response and provides long-term protection (Hoes et al., 2021). It can significantly reduce the risk of cervical cancer—the second most common cancer among women worldwide—and help prevent other cancers such as anal, penile, and oropharyngeal (Cheng et al., 2020). In addition to preventing cancers, HPV vaccination also prevents genital warts and contributes to community-wide protection through herd immunity (Xu et al., 2024). To support these health efforts, individuals are encouraged to communicate effectively with their families and healthcare providers. This includes using credible sources like the CDC, asking informed questions, and dispelling common myths—such as the false belief that the vaccine promotes early sexual activity (Kassymbekova et al., 2023).
SMART Goals and Evaluation Based on Healthy People 2030
Three SMART goals were outlined at the start of this initiative. First, by the session’s end, 90% of participants should correctly identify at least three key facts about HPV and its cancer connection. Second, at least 80% of attendees should commit to scheduling the HPV vaccine within 30 days. Third, 85% of participants should leave with increased confidence in discussing HPV vaccination. These goals guide the learning process and provide measurable outcomes for health promotion.
The evaluation results show strong performance in achieving most goals. A total of 92.5% correctly identified key facts about HPV, fulfilling the first goal. While only 75% committed to scheduling their vaccine, this fell short of the second goal. The third goal was achieved, with 85% reporting increased confidence in discussing HPV vaccination. Nonetheless, some participants—particularly teens—were hesitant to make vaccination decisions without first consulting their families. Additionally, a few participants lacked full confidence in confronting vaccine myths. Improvements for future sessions may include involving family members in discussions, providing additional role-play scenarios, and extending the session time to foster better engagement.
The session also aligns with Healthy People 2030 objectives, which emphasize increased HPV vaccination rates and community education. Despite slightly missing the 80% vaccine initiation target, the session succeeded in enhancing knowledge and improving health literacy among participants. Future improvements may include stronger myth-busting content, more evidence-based discussions on vaccine safety, and ongoing follow-up communication with hesitant participants. These changes will help to meet national health goals and improve community health outcomes.
Summary
| Presentation Segment | Details | Outcomes & Recommendations |
|---|---|---|
| Introduction and Roadmap | Introduced HPV health concerns for ages 11–26 in Schwenksville, PA. Presentation guided by SMART goals and Healthy People 2030. Outlined focus areas: HPV facts, vaccine benefits, communication strategies, and evaluation tools. | Structured, engaging session design targeting HPV prevention through education and measurable objectives. |
| Key HPV Info & Communication Strategies | Explained HPV transmission and cancer links. Highlighted benefits of early vaccination: stronger immune response, reduced cancer risk, prevention of genital warts, and herd immunity. Emphasized use of CDC data, asking questions, and myth-busting. | Strong educational content. Recommended deeper myth-busting activities, family involvement, and more structured discussions to address participant uncertainty. |
| SMART Goals & Evaluation Summary | Goals: 90% HPV knowledge, 80% vaccine commitment, 85% communication confidence. Achieved 92.5% HPV knowledge and 85% confidence. Fell short of vaccine commitment at 75%. Highlighted youth hesitation and informational gaps. | Revisions needed: more time, role-play practice, family inclusion, and follow-up sessions. Aligns with Healthy People 2030, but needs enhanced strategies to increase vaccine commitment and correct misinformation. |
References
Cheng, L., Wang, Y., & Du, J. (2020). Human papillomavirus vaccines: An updated review. Vaccines, 8(3), 391. https://doi.org/10.3390/vaccines8030391
Hoes, J., Pasmans, H., Schurink-van ’t Klooster, T. M., van der Klis, F. R. M., Donken, R., Berkhof, J., & de Melker, H. E. (2021). Review of long-term immunogenicity following HPV vaccination: Gaps in current knowledge. Human Vaccines & Immunotherapeutics, 18(1). https://doi.org/10.1080/21645515.2021.1908059
Huber, J., Mueller, A., Sailer, M., & Regidor, P.-A. (2021). Human papillomavirus persistence or clearance after infection in reproductive age. What is the status? Review of the literature and new data of a vaginal gel containing silicate dioxide, citric acid, and selenite. Women’s Health, 17.
Kassymbekova, Z., Zhumatova, G., Turgunova, L., & Tuleuova, B. (2023). Communication strategies in health promotion: Addressing vaccine hesitancy. Journal of Public Health Research, 12(2), 175–183.
NURS FPX 4055 Assessment 4 Health Promotion Plan Presentation
U.S. Department of Health and Human Services. (n.d.). Healthy People 2030: Immunization and Infectious Diseases. https://health.gov/healthypeople
Xu, M., Li, J., Huang, Y., & Cao, H. (2024). Community immunity through HPV vaccination: The path to health equity. Global Health Reports, 7(1), 45–51.
